Drug intelligence / Profile preview

Chuanxiaokang Oral Solution

Development stage: Unknown
Lead developer: Hunan Academy of Chinese Medicine
Administration: Oral

Overview

Chuanxiaokang Oral Solution is a Traditional Chinese Medicine (TCM) formulation developed by the Hunan Provincial Institute of Traditional Chinese Medicine for the treatment of pediatric bronchial asthma. It is specifically indicated for the 'cold wheezing' pattern (Han-Xiao) during acute attacks. The drug has been evaluated in a randomized, double-blind Phase III clinical trial in China, comparing its efficacy and safety to the Xiao Qinglong Mixture in children with mild to moderate bronchial asthma. The formulation is designed to relieve symptoms of wheezing and coughing by addressing the TCM-defined pathology of cold-phlegm obstruction in the lungs.

Brand names: Chuanxiaokang Oral Solution
Other names: Chuanxiaokang Koufuye

Beyond the preview

Go deeper on Chuanxiaokang Oral Solution.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chuanxiaokang Oral Solution.

Explore the full profile